Phase I/II Study of LY231514 Plus Cisplatin in Patients With Malignant Pleural Mesothelioma
Phase 1/Phase 2
20 Years
75 Years
20 Years
75 Years
Not Enrolling
Both
Malignant Pleural Mesotherioma
Both
Malignant Pleural Mesotherioma
Trial Information
Phase I/II Study of LY231514 Plus Cisplatin in Patients With Malignant Pleural Mesothelioma
Inclusion Criteria:
- Inapplicable for radical operation
- Not received prior systemic chemotherapy
- Performance status: 0-1
Exclusion Criteria:
- Having a history of sensitivity to platinum agent, folic acid or vitamin B12
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
To determine the recommended dose of LY231514 and cisplatin combination therapy, Response Rate
Principal Investigator
Call 1-877-CTLILLY(1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time(UTC/GMT - 5 hours, EST)
Investigator Role:
Study Director
Investigator Affiliation:
Eli Lilly and Company
Authority:
Japan: Ministry of Health, Labor and Welfare
Study ID:
5249
NCT ID:
NCT00251550
Start Date:
October 2005
Completion Date:
August 2006
Related Keywords:
- Malignant Pleural Mesotherioma
- Mesothelioma
Name | Location |
|---|
